Name: Latest research reports of Cohance Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Cohance Lifesciences Ltd.

NSE: COHANCE | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Underperformer

950.7500 9.20 (0.98%)

NSE Aug 12, 2025 15:31 PM

New 52W Low in past week

Volume: 89,141

Cohance Lifesciences Ltd.

29 May 2025

950.75

0.98%

Cohance Lifesciences (BUY): To remain on a high growth trajectory

Buy: Cohance Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

4QFY25 consolidated proforma sales were 11.4% above our estimates; EBITDA/APAT was -0.4% and -5.9% below estimates

Institutional Investors have decreased holdings from 27.66% to 18.64% in Jun 2025 qtr